When will the SETHOTOPE patents expire, and when will generic SETHOTOPE be available?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	SETHOTOPE	selenomethionine se-75	INJECTABLE;INJECTION	017047-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

EXECUTIVE SUMMARY

Sethotope (Thallium T201 Chloride) is a diagnostic radiopharmaceutical used for myocardial imaging. The market for diagnostic imaging agents, particularly in cardiology, is driven by the increasing prevalence of cardiovascular diseases and the demand for non-invasive diagnostic tools. Sethotope faces competition from alternative imaging modalities and newer radiopharmaceuticals. Its market position and future investment potential are contingent upon factors including regulatory approvals, manufacturing capabilities, pricing strategies, and the competitive landscape.

WHAT IS SETHOTOPE'S PRIMARY CLINICAL APPLICATION AND MARKET SEGMENT?

Sethotope is a radioactive isotope used in nuclear cardiology for myocardial perfusion imaging. Its primary application is to detect and assess the extent of coronary artery disease (CAD) by visualizing blood flow to the heart muscle at rest and under stress. This diagnostic procedure helps physicians evaluate the severity of blockages in coronary arteries and guide treatment decisions for patients presenting with symptoms of ischemia or suspected CAD.

The market segment for Sethotope is within the broader diagnostic imaging agents sector, specifically focusing on radiopharmaceuticals for cardiac diagnostics. This market is influenced by:

Prevalence of Cardiovascular Diseases: Global statistics indicate a high and rising incidence of CAD, hypertension, and heart failure, necessitating robust diagnostic tools. The World Health Organization estimates that cardiovascular diseases remain the leading cause of death globally. [1]
Demand for Non-Invasive Imaging: Patients and healthcare providers increasingly favor non-invasive diagnostic methods over invasive procedures like angiography when clinically appropriate.
Technological Advancements: Developments in SPECT (Single-Photon Emission Computed Tomography) and PET (Positron Emission Tomography) imaging technologies impact the demand for specific radiotracers.

WHAT ARE THE KEY REVENUE DRIVERS AND MARKET GROWTH FACTORS FOR SETHOTOPE?

The revenue drivers for Sethotope are primarily linked to its utilization in diagnostic cardiology procedures. Key growth factors include:

Aging Global Population: As the population ages, the incidence of cardiovascular diseases rises, leading to increased demand for diagnostic imaging.
Increased Screening and Early Detection: Growing emphasis on early detection and preventive cardiology contributes to higher utilization of diagnostic tests like myocardial perfusion imaging.
Reimbursement Policies: Favorable reimbursement rates from government payers (e.g., Medicare, Medicaid) and private insurers for diagnostic procedures utilizing Sethotope are critical for market adoption and revenue generation. [2]
Geographic Expansion: Expansion into emerging markets where access to advanced cardiovascular diagnostics is growing can drive incremental revenue.
Clinical Utility and Physician Preference: Established clinical data supporting Sethotope's diagnostic accuracy and physician familiarity/preference contribute to sustained demand.

WHO ARE THE MAJOR COMPETITORS AND ALTERNATIVE DIAGNOSTIC MODALITIES?

Sethotope competes with both other radiopharmaceuticals and alternative diagnostic imaging technologies.

Direct Radiopharmaceutical Competitors:

Technetium-99m (Tc-99m) labeled agents: Tc-99m sestamibi (e.g., Cardiolite, MIBI) and Tc-99m tetrofosmin (e.g., Myoview) are widely used and are considered direct competitors. They offer similar diagnostic capabilities with generally lower radiation doses to the patient and easier availability of the parent isotope. [3]
Other SPECT agents: Agents like Thallium-201 chloride (Sethotope) have been historically significant but are often compared against Tc-99m agents.
PET agents: Rubidium-82 chloride and N-13 ammonia are used in PET myocardial perfusion imaging, offering higher resolution and faster imaging times compared to SPECT, representing a significant technological shift and competition. [4]

Alternative Diagnostic Modalities:

Coronary CT Angiography (CCTA): This non-invasive imaging technique uses computed tomography to visualize the coronary arteries and detect blockages. It has gained considerable traction due to its speed and ability to rule out significant CAD. [5]
Stress Echocardiography: Utilizes ultrasound to assess heart function and wall motion abnormalities under stress, providing functional information about myocardial perfusion.
Cardiac Magnetic Resonance Imaging (CMR): Offers high-resolution anatomical and functional imaging, including stress perfusion studies, with no ionizing radiation.

The competitive landscape is characterized by a shift towards agents with improved dosimetry, higher image resolution, and faster acquisition times.

WHAT ARE THE REGULATORY AND MANUFACTURING CONSIDERATIONS FOR SETHOTOPE?

The production and distribution of radiopharmaceuticals like Sethotope are subject to stringent regulatory oversight and complex manufacturing processes.

Regulatory Considerations:

FDA Approval: Sethotope requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for its sale and use. This includes rigorous review of safety, efficacy, and manufacturing processes. [6]
Good Manufacturing Practices (GMP): Manufacturers must adhere to strict GMP regulations to ensure the quality, purity, and potency of the radiopharmaceutical.
Radioactive Material Handling: Compliance with regulations governing the handling, transport, and disposal of radioactive materials is mandatory, involving agencies like the Nuclear Regulatory Commission (NRC) in the U.S. [7]
Labeling and Packaging: Specific requirements for labeling, packaging, and accompanying information are enforced to ensure safe and effective use.
Post-Market Surveillance: Ongoing monitoring for adverse events and product quality is required.

Manufacturing Considerations:

Isotope Production: Thallium-201 is a cyclotron-produced isotope. The availability and cost of cyclotron time and target materials are critical factors. The half-life of Thallium-201 is approximately 73 hours, requiring timely production and distribution. [8]
Radiolabeling Process: The process of labeling the thallium chloride with the radioactive Tl-201 isotope must be precise and efficient to maximize yield and minimize impurities.
Cold Kit Production: The non-radioactive components (cold kits) used in the preparation of the final radiopharmaceutical must also be manufactured under strict GMP conditions.
Supply Chain and Distribution: Radiopharmaceuticals have a limited shelf-life and require specialized cold-chain logistics for rapid delivery to hospitals and imaging centers. Disruptions in the supply chain, including the availability of the parent isotope, can impact product availability.
Quality Control: Extensive quality control testing is performed at multiple stages of manufacturing to ensure the product meets all specifications.

The limited number of cyclotron facilities and specialized radiopharmaceutical manufacturers can create bottlenecks and influence market supply.

WHAT ARE THE FINANCIAL METRICS AND MARKET VALUATION FACTORS FOR A SETHOTOPE-FOCUSED COMPANY?

For a company primarily focused on Sethotope, financial metrics and valuation factors would encompass several key areas:

Financial Metrics:

Revenue: Primarily driven by unit sales of Sethotope to hospitals and imaging centers, often sold as a ready-to-administer product or as part of a kit.
Cost of Goods Sold (COGS): Includes costs associated with isotope production, manufacturing, quality control, and packaging. The cost of Thallium-201 and cyclotron operation significantly impacts COGS.
Gross Profit Margin: Reflects the profitability of the product after accounting for direct manufacturing costs.
Operating Expenses: Include R&D (for process improvements or new applications), sales and marketing, regulatory affairs, and general administrative costs.
Net Income: Profitability after all expenses, taxes, and interest.
Cash Flow: Particularly important given the capital-intensive nature of radiopharmaceutical manufacturing and the need for ongoing R&D and regulatory compliance.

Market Valuation Factors:

Market Share: The percentage of the myocardial perfusion imaging market held by Sethotope.
Sales Growth Rate: The historical and projected annual growth in Sethotope sales.
Competitive Positioning: Sethotope's standing relative to Tc-99m agents and newer PET tracers.
Patent Landscape: The existence and expiry dates of patents covering Sethotope or its manufacturing processes can significantly impact long-term profitability and competitive advantage.
Pricing Power: The ability to set and maintain prices, influenced by reimbursement rates and competition.
Pipeline and Diversification: While the focus is on Sethotope, the company's broader portfolio or pipeline of other diagnostic agents or therapeutic products influences overall valuation.
Manufacturing Capacity and Reliability: The ability to consistently produce and deliver Sethotope without supply chain disruptions is crucial.
Regulatory Compliance History: A strong track record of regulatory compliance enhances investor confidence.
Management Team Experience: Expertise in radiopharmaceutical manufacturing, regulatory affairs, and market strategy is highly valued.

WHAT ARE THE PRINCIPAL RISKS AND CHALLENGES ASSOCIATED WITH INVESTING IN SETHOTOPE?

Investing in Sethotope or a company heavily reliant on it carries specific risks and challenges:

Technological Obsolescence: The rapid evolution of diagnostic imaging may lead to the displacement of SPECT by PET or newer non-nuclear imaging modalities like advanced CCTA or CMR, which offer higher resolution or different diagnostic information. [4, 5]
Competition from Tc-99m Agents: Technetium-99m-based radiopharmaceuticals are widely used, generally have better dosimetry, and are more readily available due to the mature supply chain for Tc-99m.
Supply Chain Vulnerabilities: The production of Thallium-201 is dependent on cyclotron availability and specialized manufacturing. Disruptions due to equipment failure, raw material shortages, or geopolitical factors can impact supply.
Regulatory Hurdles: Changes in regulatory requirements, delays in approvals for new indications or manufacturing site changes, or unexpected findings during post-market surveillance can negatively affect the product.
Reimbursement Pressures: Government and private payers may reduce reimbursement rates for diagnostic procedures, impacting the profitability of utilizing Sethotope.
Limited Therapeutic Applications: Sethotope is a diagnostic agent. Unlike some radiopharmaceuticals that have therapeutic applications (e.g., Lutetium-177 PSMA for prostate cancer), Sethotope's market is confined to diagnostics, limiting its growth potential.
High Manufacturing Costs: The cost of cyclotron production, specialized facilities, and stringent quality control can result in higher COGS compared to simpler diagnostic agents.
Radiation Dose Concerns: While improvements have been made, any perception of a higher radiation dose compared to competing agents can influence physician choice.
Market Size Limitations: The market for myocardial perfusion imaging, while significant, may have reached maturity in developed regions, limiting substantial organic growth for an established product.

KEY TAKEAWAYS

Sethotope (Thallium T201 Chloride) is a well-established diagnostic radiopharmaceutical for myocardial perfusion imaging. Its market is driven by the global burden of cardiovascular disease and the demand for non-invasive diagnostics. However, it faces intense competition from Technetium-99m-based agents and advanced imaging modalities like PET, CCTA, and CMR. Regulatory compliance and a robust, specialized manufacturing supply chain are critical. Investment viability is contingent on competitive pricing, consistent supply, favorable reimbursement, and the ability to navigate technological evolution and potential obsolescence.

FREQUENTLY ASKED QUESTIONS

What is the primary advantage of Sethotope over Technetium-99m-based myocardial perfusion agents? Historically, Thallium-201 showed superior lung uptake and was used for some diagnostic parameters not directly captured by Tc-99m agents in early SPECT imaging protocols. However, modern Tc-99m agents often offer better dosimetry and wider availability. [3]
How does the half-life of Thallium-201 impact its manufacturing and distribution? With a half-life of approximately 73 hours, Thallium-201 requires efficient and timely production and distribution to ensure maximum radioactivity at the time of patient administration. This necessitates close integration between production facilities and end-users. [8]
What is the typical cost structure for producing and administering Sethotope? Costs include isotope production (cyclotron time and target materials), radiolabeling, cold kit manufacturing, quality control, specialized packaging, cold-chain logistics, and the cost of the SPECT imaging procedure itself, including equipment and personnel.
Are there any potential new indications or applications being explored for Sethotope? While Sethotope's primary role is well-established in myocardial perfusion imaging, research into novel applications for radiotracers is ongoing, though significant new indications for Tl-201 in cardiology are not widely anticipated given current technological trends.
What regulatory changes could most significantly impact the market for Sethotope? Changes in FDA or equivalent regulatory body requirements for radiopharmaceuticals, new imaging guidelines from professional bodies (e.g., ACC, AHA), or shifts in reimbursement policies by CMS or major private insurers would have the most substantial impact. [2]

CITATIONS

[1] World Health Organization. (2023). Cardiovascular diseases (CVDs). Retrieved from https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) [2] Centers for Medicare & Medicaid Services. (n.d.). Medicare Part B drug payment. Retrieved from https://www.cms.gov/Medicare/Medicare-Part-B-Drug-Payment [3] Dhekne, M. A., & Shrikhande, J. A. (2016). Technetium-99m radiopharmaceuticals for myocardial perfusion imaging. Indian Journal of Nuclear Medicine, 31(1), 3–8. [4] Taub, R. B., & Van Nimwegen, G. R. (2021). Positron Emission Tomography in Cardiology. Seminars in Nuclear Medicine, 51(4), 347–362. [5] Knuuti, J., Minerva, G., Saraste, A., et al. (2020). 2019 ESC Guidelines on the diagnosis and management of chronic coronary syndromes. European Heart Journal, 41(3), 407–477. [6] U.S. Food & Drug Administration. (n.d.). Radiopharmaceuticals. Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/radiopharmaceuticals [7] U.S. Nuclear Regulatory Commission. (n.d.). Radioactive Materials. Retrieved from https://www.nrc.gov/about-nrc/radiation/materials.html [8] U.S. Department of Energy Office of Scientific and Technical Information. (n.d.). Isotope Products Database. Retrieved from https://www.isotopes.gov/

SETHOTOPE Drug Patent Profile

Which patents cover Sethotope, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for SETHOTOPE

US Patents and Regulatory Information for SETHOTOPE

SETHOTOPE (THALLIUM T201 CHLORIDE) INVESTMENT SCENARIO AND FUNDAMENTALS ANALYSIS